Cell News and Research

RSS

CJPS Medical releases VitalPoint device to improve healthcare

CJPS Medical Systems releases VitalPoint this week, a medical device capable of measuring patients' vital signs from home, while allowing direct communication with their caregiver, and generating and saving HIPAA-compliant electronic medical records.

27 Oct 2010

CHORI hosts 2nd annual international Advanced Workshop on Sickle Cell Disease

Children's Hospital & Research Center Oakland is hosting the 2nd annual international Advanced Workshop on Sickle Cell Disease October 28 and 29. This impressive conference will bring together hematologists from Pakistan, Saudi Arabia, Mexico, Venezuela, Brazil, and beyond, and the premier sickle cell experts from the United States for a dialogue on research, comprehensive care, and new treatments and therapies.

27 Oct 2010

Study: lncRNA are involved in host response to viral infection

Scientists have demonstrated for the first time that a certain class of RNA (known as long non-protein-coding RNA [lncRNA]) are involved in the host response to viral infection. These findings, published today in the online journal mBio-, could greatly change the way scientists look at the body's response to viral infection.

27 Oct 2010

VCA Clinical Fellowship awarded for epithelial ovarian cancer research

Dr Clare Scott from the Walter and Eliza Hall Institute in Melbourne, Australia, has been awarded a Victorian Cancer Agency (VCA) Clinical Fellowship to further research into an aggressive and highly lethal form of ovarian cancer.

27 Oct 2010

USAID announces LAUNCH: Health innovators

The U.S. Agency for International Development (USAID), NASA, NIKE, Inc. and the U.S. Department of State are pleased to announce those selected to participate in the LAUNCH: Health Forum. The innovators selected will participate in an event at NASA's Kennedy Space Center in Florida October 30-31, followed immediately by the launch of the Space Shuttle Discovery on November 1.

27 Oct 2010

New guideline for using ESAs drugs in cancer patients

An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia.

27 Oct 2010

Reactivating three silenced molecules may provide new strategy to treat multiple myeloma

New research links three molecules to a critical tumor suppressor gene that is often turned off in multiple myeloma, a presently incurable cancer of the blood.

27 Oct 2010

Human haptoglobin gene mutation increases risk of diabetic complications

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is a multifactorial disease of complex etiology characterized by the autoimmune destruction of pancreatic beta cells. In addition to genetic susceptibility, it is generally accepted that environmental factors play important roles in triggering disease, with virus infection having perhaps the strongest association.

27 Oct 2010

Lifestyle intervention programs result in significant weight loss for overweight and severly obese adults

Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online October 9 by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles appear in the October 27 print issue of JAMA.

27 Oct 2010

University of Padua Professor wins Paul Ehrlich and Ludwig Darmstaedter Prize

Frankfurt am Main. The chemist and biologist Professor Cesare Montecucco, 62, of the Department of Biomedical Research at the University of Padua, Italy, has won the 100,000 euro Paul Ehrlich and Ludwig Darmstaedter Prize 2011 for his contribution to research in the field of bacterial diseases, including tetanus, botulism, anthrax and Helicobacter pylori associated diseases.

27 Oct 2010

Rockwell receives SFP patent for GMP formulation

Rockwell Medical a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has received notice from the U.S. Patent and Trademark Office for patent issuance on its proprietary GMP formulation for Soluble Ferric Pyrophosphate (SFP), the Company's lead-drug candidate for treating iron deficiency anemia in ESRD patients.

27 Oct 2010

Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda

Oramed Pharmaceuticals Inc. a developer of oral drug delivery systems, announced today that its work entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," will be presented at the Tenth Annual Meeting of the Diabetes Technology Society, to be held in Bethesda, Maryland this November.

27 Oct 2010

MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.

27 Oct 2010

Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain

Oncolytics Biotech Inc. announced today that interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases was presented at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation being held in Pamplona, Spain.

27 Oct 2010

Illumina announces single flow cell version of HiSeq 2000 sequencing system

Illumina, Inc. today announced HiSeq 1000, a single flow cell version of the company's HiSeq 2000 sequencing system. HiSeq 1000 is designed for researchers who want the ease of use, industry-leading cost per gigabase (Gb) and data rate of the HiSeq 2000 but do not currently require its throughput. As their research scales, users will be able to upgrade their system to the HiSeq 2000 and double their output.

From Illumina, Inc. 27 Oct 2010

Long non-protein coding RNAs respond to SARS virus infection, says study

For the first time, scientists have discovered that a poorly understood class of RNA produced in a mammal's cells during a respiratory virus attack may affect the outcome of the infection. Their findings are reported today in mBio, a journal of the American Society for Microbiology.

27 Oct 2010

Illumina 2010 third quarter revenue increases 50% to $237.3 million

Illumina, Inc. today announced its financial results for the third quarter of 2010.

From Illumina, Inc. 27 Oct 2010

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

26 Oct 2010

Aastrom Biosciences and ATEK Medical enter new strategic partnership

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, and ATEK Medical, a leading medical device manufacturer, today announced the formation of a new strategic partnership in which ATEK Medical will supply key components and technology for use in Aastrom's proprietary cell manufacturing process.

26 Oct 2010

Cryo-Cell formalizes industry-exclusive agreement with MedTech For Solutions GPO

Cryo-Cell International, Inc., one of the world's largest and most established family cord blood banks and global stem cell innovators, today announced at the annual meeting of the American Society of Reproductive Medicine (ASRM) that the Company has formalized an industry-exclusive agreement with MedTech For Solutions, Inc., a Group Purchasing Organization (GPO) representing a member network of 115 practices specializing in reproductive medicine, which operates in conjunction with The Broadlane Group.

26 Oct 2010